Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans

Inflammation Research

Volumn 60, Issue 12, 2011, Pages 1107-1112

  Church, Martin K ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bilastine; Cetirizine; Wheal and flare

Indexed keywords

BILASTINE; CETIRIZINE; HISTAMINE; PLACEBO;

ADULT; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN FLARE; SKIN MANIFESTATION; SKIN TEST; SOMNOLENCE; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CETIRIZINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; PIPERIDINES; SKIN TESTS; URTICARIA; YOUNG ADULT;

EID: 84855247688     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0373-y     Document Type: Article

References (24)

1. J Bousquet N Khaltaev AA Cruz J Denburg WJ Fokkens A Togias, et al. 2008 Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 Suppl 86 8 160 18331513 10.1111/j.1398-9995.2007.01620.x (Pubitemid 351357811)
2. GF Clough P Boutsiouki MK Church 2001 Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin Allergy 56 10 985 988 11576078 10.1034/j.1398-9995.2001.00204.x 1:CAS:528:DC%2BD3MXnsFWhs7w%3D (Pubitemid 32835604)
3. KJ Denham P Boutsiouki GF Clough MK Church 2003 Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin Inflamm Res 52 10 424 427 14520518 10.1007/s00011-003-1193-5 1:CAS:528:DC%2BD3sXoslChu70%3D (Pubitemid 37260429)
4. A Purohit M Melac G Pauli N Frossard 2003 Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin Br J Clin Pharmacol 56 4 388 394 12968983 10.1046/j.1365-2125.2003.01897.x 1:CAS:528:DC%2BD3sXosFCls7g%3D (Pubitemid 37188133)
5. U Darsow J Ring E Scharein B Bromm 1996 Correlations between histamine-induced wheal, flare and itch Arch Dermatol Res 288 8 436 441 8844121 10.1007/BF02505231 1:CAS:528:DyaK28Xlt1Ohs7c%3D (Pubitemid 26282736)
6. P Kumar Q Shen CD Pivetti ES Lee MH Wu SY Yuan 2009 Molecular mechanisms of endothelial hyperpermeability: implications in inflammation Expert Rev Mol Med 11 e19 19563700 10.1017/S1462399409001112
7. JH Entrican JG Simpson AL Stalker 1971 The effects of histamine and bradykinin on the post-capillary venule J Pathol 104 3 3 5124986 1:STN:280:DyaE38%2FlsVGnug%3D%3D
8. J Raud 1989 Intravital microscopic studies on acute mast cell-dependent inflammation Acta Physiol Scand Suppl 578 1 58 2471389 1:STN:280: DyaL1M3mvFKqsA%3D%3D
9. MC Glyn JG Lawrenson BJ Ward P Clark 2008 Rho kinase-mediated reduction in cardiac capillary endothelial cell dimensions, in situ, against flow Microcirculation 28 1 16 10.1080/10739680701567097
10. M Schmelz K Michael C Weidner R Schmidt HE Torebjork HO Handwerker 2000 Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 11 3 645 648 10718329 10.1097/00001756-200002280-00041 1:STN:280: DC%2BD3c7otFamtQ%3D%3D (Pubitemid 30120491)
11. M Schmelz 2001 A neural pathway for itch Nat Neurosci 4 1 9 10 11135635 10.1038/82956 1:CAS:528:DC%2BD3MXitVehtA%3D%3D (Pubitemid 32095518)
12. R Corcostegui L Labeaga A Innerarity A Berisa A Orjales 2005 Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity Drugs R D 6 6 371 384 16274260 10.2165/00126839-200506060-00005 1:CAS:528:DC%2BD28XivVWlsA%3D%3D (Pubitemid 41633390)
13. R Corcostegui L Labeaga A Innerarity A Berisa A Orjales 2006 In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist Drugs R D 7 4 219 231 16784247 10.2165/00126839- 200607040-00002 1:CAS:528:DC%2BD28Xos1yku7o%3D (Pubitemid 43927202)
14. T Zuberbier A Oanta E Bogacka I Medina F Wesel P Uhl, et al. 2010 Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study Allergy 65 4 516 528 19860762 10.1111/j.1398-9995.2009.02217.x 1:CAS:528:DC%2BC3cXkvVehsbs%3D
15. F Horak P Zieglmayer R Zieglmayer P Lemell 2010 The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber Inflamm Res 59 5 391 398 19943178 10.1007/s00011-009-0117-4 1:CAS:528:DC%2BC3cXkslaksb0%3D
16. P Kuna C Bachert Z Nowacki P van Cauwenberge I Agache L Fouquert, et al. 2009 Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study Clin Exp Allergy 39 9 1338 1347 19438584 10.1111/j.1365-2222.2009.03257.x 1:CAS:528:DC%2BD1MXhtFOrurvE
17. C Bachert P Kuna F Sanquer P Ivan V Dimitrov MM Gorina, et al. 2009 Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients Allergy 64 1 158 165 19132976 10.1111/j.1398-9995.2008.01813.x 1:CAS:528:DC%2BD1MXitl2qur8%3D
18. N Jauregizar L de la Fuente ML Lucero A Sologuren N Leal M Rodriguez 2009 Pharmacokinetic-pharmacodynamic modelling of the antihistaminic H1-effect of bilastine Clin Pharmacokinet 48 8 543 554 19705924 10.2165/11317180-000000000- 00000 1:CAS:528:DC%2BD1MXhtlWksrzP
19. M Staevska TA Popov T Kralimarkova C Lazarova S Kraeva D Popova, et al. 2010 The effectiveness of levocetirizine and desloratadine in up to four-times conventional doses in difficult-to-treat urticaria J Allergy Clin Immunol 125 676 682 20226302 10.1016/j.jaci.2009.11.047 1:CAS:528:DC%2BC3cXjtFOqtLo%3D
20. T Zuberbier R Asero C Bindslev-Jensen CG Walter MK Church AM Gimenez-Arnau, et al. 2009 EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria Allergy 64 10 1427 1443 19772513 10.1111/j.1398-9995.2009.02178.x 1:CAS:528:DC%2BD1MXhtlSktL%2FJ
21. 194 Mol Pharmacol 61 2 391 399 11809864 10.1124/mol.61.2.391 1:CAS:528: DC%2BD38Xos1OnsQ%3D%3D (Pubitemid 34112814)
22. 1- antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Safety. 2011;10:779-93.
23. AH Schinkel 1999 P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Deliv Rev 36 2-3 179 194 10837715 10.1016/S0169-409X(98)00085-4 1:CAS:528:DyaK1MXhvVCgu7Y%3D (Pubitemid 29121971)
24. C Chen E Hanson JW Watson JS Lee 2003 P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists Drug Metab Dispos 31 3 312 318 12584158 10.1124/dmd.31.3.312 1:CAS:528:DC%2BD3sXhsFKltL8%3D (Pubitemid 36249686)